Serum HBsAg kinetics and usefulness of interferon‐inducible protein 10 serum in HBeAg‐negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2893|22|12|1079-1087

ISSN： 1352-0504

Source： JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol.22, Iss.12, 2015-12, pp. : 1079-1087

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

IFNL4 rs368234815 and rs117648444 variants predict off‐treatment HBsAg seroclearance in IFN‐treated HBeAg‐negative chronic hepatitis B patients

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. 3, 2018-03 ,pp. : 417-423

John Wiley & Sons Inc

Access to resources Recommend Favorite

HBsAg loss is not an ideal indicator for discontinuing treatment of HBeAg-negative chronic hepatitis B: a case report

By Dong Pei-ling   Zhang Xin   Zhao Wen-min   Ding Hui-guo  

Journal of Infection and Chemotherapy, Vol. 19, Iss. 6, 2013-12 ,pp. : 1188-1192

Springer Publishing Company

Access to resources Recommend Favorite

Interleukin‐28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg‐negative chronic hepatitis B

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 3, 2015-03 ,pp. : 846-853

John Wiley & Sons Inc

Access to resources Recommend Favorite

Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa‐2b in HBeAg‐positive patients

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 25, Iss. 9, 2010-09 ,pp. : 1498-1506

John Wiley & Sons Inc

Access to resources Recommend Favorite

P061: Interruption of nucleos(t)ide analogue therapy in HBeAg‐negative chronic hepatitis B ‐ a new concept to achieve HBsAg reduction?

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 50-50

John Wiley & Sons Inc

Access to resources Recommend Favorite